Campuses

As France's leading biocluster, Genopole is an incubator for cutting-edge projects in biotechnology. Located in the city of Évry, just south of Paris, Genopole provides a unique environment for scientists and entrepreneurs seeking to advance research and innovation.

Discover >

Advantages

Genopole accompanies researchers, postdocs and start-up entrepreneurs through all the phases of their projects to ensure the best possible conditions for business development.

Discover >

Genopole’s citizens

Every day, at Genopole, researchers, entrepreneurs and students cross paths, share ideas and unite forces in a veritable melting pot for innovation.

Discover >

Highlights

Giving wings to research and empowering employment in our community are cornerstones of Genopole's mission. Catch up on recent scientific advances, the accomplishments of our biotech actors and the events that enliven the biocluster.

Discover >

Innovate with us

Discover >
Highlights

Global Bioenergies launches its makeup brand


Global Bioenergies was created in 2008 by Marc Delcourt at Genopole. In his company’s R&D laboratory, the Cosmetic Formulation Unit created in November 2019 has conjugated bio-based ingredients and long-lasting performance in an unprecedented line of mascaras and eye shadows.
Press release >
LAST - Makeup by Global Bioenergies LAST - Makeup by Global Bioenergies

Global Bioenergies has achieved a historic step in its commercial development with the launch of LAST®, a makeup brand combining natural ingredients and long-lasting performance.

Marc Delcourt - CEO of Global BioenergiesInterview with Marc Delcourt, founder and CEO of Global Bioenergies

Can you tell us more about your manufacturing process for the isododecane used in your makeup products?

Marc Delcourt : “In 2019, we created a Cosmetic Formulation Unit in our laboratory in Évry. That unit developed our first prototypes of eye cosmetics, for which isododecane is the main ingredient. Isododecane is an assembly of three isobutylene molecules that we produce from renewable resources such as beets, straw or wood shavings, among others.

Microorganisms transform the sugars of these plant resources into isobutylene via an exclusive, patented synthetic biology process that we have been developing over the last ten years. Those prototypes have been perfected and industrialized in partnership with one of Europe’s main makeup manufacturers. We thus are bringing to the cosmetics market a line of products using bio-based isododecane. That molecule is the primary ingredient in long-lasting mascaras and lipsticks, representing as much as 25 to 50% of their formulas. To date, isododecane has always been petroleum-based.”

Your products prove that “natural” and “long-lasting” can walk hand-in-hand?

Marc Delcourt : “Natural makeup products already exists, but ‘long-lasting’ has never really been applicable to them. Our products are indeed the first to genuinely unite those two qualities. Isododecane is the key and majority ingredient in long-lasting makeup. By biosourcing the isododecane and completing the formula with other natural ingredients, we are able to attain a high rate of naturality (greater than 90%) while maintaining performance equal to that of the best makeup products on the market.”

Why did you choose to invest in the cosmetics sector?

Marc Delcourt : “The objective of our industrial biology company is to provide an alternative to the petrochemistry industry. We are not abandoning biofuels, but it is currently difficult to compete against petroleum-based fuels as they remain very inexpensive. We thus chose to invest in cosmetics, a sector where customers are clamoring for natural products and thus willing to pay the price needed to cover the higher cost of bio-based isododecane. We needed to acquire all the competencies necessary for cosmetics: formulations, marketing, packaging, e-commerce, regulations. But the agility of our company made that possible.”

What are your commercial development perspectives?

Marc Delcourt : “We are currently moving into commercialization. All turnover to date has resulted from partnerships. We will now generate direct recurrent revenue. The initial run will count about 300,000 units, which, at 20 euros per unit, represents a market value of six million euros. We foresee a scale increase starting in 2022 with the sale of makeup ingredients to market leaders to energize the move to naturality for the entire sector. Thereafter, we’ll enlarge our activities to other cosmetics specialties, like hair care and dermo-cosmetics.”

A full range of products


Tested under dermatological control, the brand LAST® currently comprises three product categories: mascaras, eyebrow fillers and eye shadows, all offering a duration of at least 24 hours.
Counting color choices, the range counts 18 references currently under production in a French facility.

Commercialization in France and England at the website www.colors-that-last.com will begin in June for the mascaras and eye shadows, and extend to lipsticks (14 colors) for the fall season.

The product line targets active women looking for long-lasting makeup and all women prioritizing natural products.

The mascaras (9 mL) will sell for €25, the eyebrow fillers (2.5 mL) for €18 and the eye shadows (5 mL) for €24.

The line comprises vivid shades like yellow, green and blue, as well as more classic shades like taupe, brown, kaki and black.

Article posted on 6 May 2021

Share
Highlights

Latest news


Laina Freyer directrice scientifique, Felome

Felome Launches the Commercialization of Genetic Analyses for Companion Cats

Felome will begin the commercialization of a service offering genetic analyses for companion cats, to reveal their predispositions to over 50 diseases, identify their main physical traits, and their similarities with 14 types of breeds.

Discover
l'équipe iGEM 2023 Evry Paris-Saclay - Médaille d'or et p

A prize and gold for the 2023 Évry Paris-Saclay iGEM team

The international synthetic biology competition iGEM celebrated its 20th anniversary. From across the globe, the event drew more than 7,000 students in 400 teams from 66 countries. Genopole was there, among other actors in synthetic biology, to present the biocluster's advantages at its stand, and support the 17 students of the Évry Paris-Saclay team and their outstanding project, OptoGenEYEsis.

Discover
Ibisc - Genopole's Laboratory

IBISC – Structure prediction for RNA complexes

passes a milestone in structure prediction for RNA complexes, key players in cell biology.

Discover
IBISC: A first predictive tool for the emerging field of bifunctional RNA

IBISC: A first predictive tool for the emerging field of bifunctional RNA

The IBISC laboratory has developed IRSOM2, an unprecedented bioinformatics tool for the prediction of bifunctional RNA, a relatively recently discovered class of RNA showing both an ability to code for proteins and an ability to perform biological roles.

Discover
Integrating informatics, structural biology and in vivo exploration for the discovery of new medicines

SABNP & Synsight: discovery of new medicines

SABNP and Synsight have validated an integrated, drug discovery approach uniting informatics, structural biology and in vivo exploration.

Discover
Alexis Biton and Paul Carouen - Genopole - visiting the Research Triangle Park (USA) accompanied by 3 Genopole's companies

Genopole strengthens its ties with the Research Triangle Park

From Monday March 20 to Thursday March 24, Genopole's Partnership & Business Development team visited the Research Triangle Park biopark in North Carolina to strengthen scientific and industrial collaborations.

Discover
Lambe - Genopole's laboratory

Lambe: Detecting coagulation biomarkers with a natural nanopore

The Lambe laboratory showed proof of concept for a coagulation biomarker detection technology based on a natural nanopore.

Discover
Andrew Tolonen's team within the unit of Genomics Metabolics (Genoscope - CEA)

Genoscope: Biomanufacturing with bacteria

A team led by Andrew Tolonen has developed a method to optimize the genetic engineering of Clostridium genus bacteria for biotech applications

Discover
l’équipe « Dystrophies musculaires progressives » du laboratoire Généthon

Shining light on a key mechanism of Duchenne muscular dystrophy

A Genethon team has provided new insights on a complex genetic mechanism involved in mitochondrial dysfunction in Duchenne muscular dystrophy.

Discover
A trio of genome sites associated with arterial hypertension

A trio of genome sites associated with arterial hypertension

Researchers from the CNRGH and PARCC have identified three loci associated with an increased risk of developing primary hyperaldosteronism, a leading cause of arterial hypertension.

Discover
Genoscope - CNS - Genopole's laboratory

The story of the domestic donkey told by its genome

Genoscope participated in the sequencing of the DNA of 250 donkeys in a study revealing the domestication of this species highly contributive to human activities to this day.

Discover
Galaxy-SynBioCAD: accelerating the arrival of green chemistry

Galaxy-SynBioCAD: accelerating the arrival of green chemistry

Conceived by the Genomics Metabolics Unit, Galaxy-SynBioCAD accelerates biological design and engineering for the production of next generation chemical compounds.

Discover
Equipe Sysfate de l'UMR 8030 - projet T-Fitness

T-FITNESS: Toward empowering CAR-T therapies for solid tumors

The Genopole team SysFate is participating in the international project T-FITNESS. The project, selected by the European Innovation Council, aims to resolve the difficulty of T-cell exhaustion in CAR-T therapies for solid tumors.

Discover
Ynsect & Genoscope : Vers la sélection génomique des insectes d’élevage

Toward the genomic selection of farmed insects

France is historically a land of livestock farming. Cows for meat or milk, sheep, pigs, fowl of all sorts; France rears them all. And insects! With its genomic selection project for Tenebrio molitor beetles, the Genopole company Ÿnsect and its biocluster partner, the sequencing center Genoscope, are making France a pioneer in insect farming.

Discover
Couverture de la revue Cell Genomics - Le plancton

A feat in the study of planktonic life

A Genoscope research team was part of a pioneering study in environmental genomics. The researchers were able to at least partially reconstitute the genomes of close to 700 eukaryote species.

Discover
Logos Istem & Généthon

A two-drug combination to treat limb-girdle muscular dystrophies and cystic fibrosis

The I-Stem and Genethon laboratories have identified a promising drug combination in the setting of three genetic diseases sharing similar molecular mechanisms.

Discover
IBISC - IA qui diagnostique et explique grâce à un réseau de neurones

An artificial intelligence to diagnose and explain

The IBISC laboratory has conceived an architecturally-innovative neural network able to provide not only a diagnostic prediction but also a biological explanation.

Discover
Christophe Lanneau - Research & Platforms Department Director

News from the human genome

The 1 April edition of Science announced the publication of the human genome with the previously-missing 8% now added to it. Comments from the Genopole Director of Research.

Discover
CNRGH - Consequences of phthalate exposure during pregnancy

Consequences of phthalate exposure during pregnancy

Jörg Tost and his team of the National Center of Human Genomics Research (CNRGH; CEA) were part of a large collaborative study aimed at determining the genome-wide correlation between phthalate exposure during pregnancy and methylation of placental DNA.

Discover
INtegrare / Généthon - Efficacité à long terme de la thérapie génique d’un déficit immunitaire

Long-term efficacy for an immunodeficiency gene therapy

A gene therapy conceived by Genethon has been shown to confer long-term efficacy against Wiskott-Aldrich syndrome, an immune deficiency disorder.

Discover
View all >
With the support from
Région île de France